{
  "trial_id": "NCT02902120",
  "trial_group": "chronic kidney disease",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, gender, renal function (GFR), HCV viremia levels, HCV genotype, liver disease staging, pregnancy status, platelet count, albumin levels, AST levels, ALT levels, history of allergy or adverse events with protease inhibitors, co-administration of specific medications, duration since renal transplantation (for post-transplant arm), dialysis status (for pre-transplant arm).",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "gender"
        ],
        [
          "Fibrosis Stage",
          "liver disease staging"
        ],
        [
          "HCV genotype post-transplant",
          "HCV genotype"
        ],
        [
          "Median baseline HCV RNA level",
          "HCV viremia levels"
        ],
        [
          "Time from transplant",
          "duration since renal transplantation (for post-transplant arm)"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Male",
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)",
        "Region of Enrollment",
        "HCV-positive donor"
      ],
      "remaining_candidate_features": [
        "renal function (GFR)",
        "pregnancy status",
        "platelet count",
        "albumin levels",
        "AST levels",
        "ALT levels",
        "history of allergy or adverse events with protease inhibitors",
        "co-administration of specific medications",
        "dialysis status (for pre-transplant arm)"
      ]
    },
    "processed-gen-response": "Age, gender, renal function (GFR), HCV viremia levels, HCV genotype, liver disease staging, pregnancy status, platelet count, albumin levels, AST levels, ALT levels, history of allergy or adverse events with protease inhibitors, co-administration of specific medications, duration since renal transplantation (for post-transplant arm), dialysis status (for pre-transplant arm)."
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, Baseline renal function (eGFR), HCV viral load, HCV genotype, Liver disease staging, AST, ALT, Albumin, Platelet count, Use of immunosuppressive therapy,",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Race (NIH/OMB)",
          "Race/Ethnicity"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ],
        [
          "HCV genotype post-transplant",
          "HCV genotype"
        ],
        [
          "Fibrosis Stage",
          "Liver disease staging"
        ]
      ],
      "remaining_reference_features": [
        "Ethnicity (NIH/OMB)",
        "HCV-positive donor",
        "Median baseline HCV RNA level",
        "Time from transplant"
      ],
      "remaining_candidate_features": [
        "Baseline renal function (eGFR)",
        "HCV viral load",
        "AST",
        "ALT",
        "Albumin",
        "Platelet count",
        "Use of immunosuppressive therapy"
      ]
    },
    "processed-gen-response": "Age, Sex: Female, Male, Race/Ethnicity, Region of Enrollment, Baseline renal function (eGFR), HCV viral load, HCV genotype, Liver disease staging, AST, ALT, Albumin, Platelet count, Use of immunosuppressive therapy"
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, HCV Genotype, HCV RNA, Liver Fibrosis Stage, eGFR, Hemoglobin, Platelet Count, Albumin, AST, ALT, Creatinine, Prior Kidney Transplant, Time Since Transplant, Immunosuppressive Regimen.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Race (NIH/OMB)",
          "Race/Ethnicity"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ],
        [
          "Fibrosis Stage",
          "Liver Fibrosis Stage"
        ],
        [
          "HCV genotype post-transplant",
          "HCV Genotype"
        ],
        [
          "Median baseline HCV RNA level",
          "HCV RNA"
        ],
        [
          "Time from transplant",
          "Time Since Transplant"
        ]
      ],
      "remaining_reference_features": [
        "Ethnicity (NIH/OMB)",
        "HCV-positive donor"
      ],
      "remaining_candidate_features": [
        "eGFR",
        "Hemoglobin",
        "Platelet Count",
        "Albumin",
        "AST",
        "ALT",
        "Creatinine",
        "Prior Kidney Transplant",
        "Immunosuppressive Regimen"
      ]
    },
    "processed-gen-response": "Age, Sex: Female, Male, Race/Ethnicity, Region of Enrollment, HCV Genotype, HCV RNA, Liver Fibrosis Stage, eGFR, Hemoglobin, Platelet Count, Albumin, AST, ALT, Creatinine, Prior Kidney Transplant, Time Since Transplant, Immunosuppressive Regimen."
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, sex, race, ethnicity, body mass index (BMI), chronic kidney disease (CKD) stage, genotype 1 HCV infection, HCV viremia, HCV antibody positivity, liver disease staging, creatinine level, glomerular filtration rate (GFR), albumin level, platelet count, aspartate aminotransferase (AST) level, alanine aminotransferase (ALT) level, Child-Pugh class, history of clinically significant allergy or adverse event with protease inhibitors, history of liver disease caused by an etiology other than HCV, history of hepatocellular carcinoma, history of HIV co-infection, history of prior exposure to HCV protease inhibitor therapy.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Race (NIH/OMB)",
          "race"
        ],
        [
          "Ethnicity (NIH/OMB)",
          "ethnicity"
        ],
        [
          "Fibrosis Stage",
          "liver disease staging"
        ],
        [
          "HCV genotype post-transplant",
          "genotype 1 HCV infection"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Male",
        "Region of Enrollment",
        "HCV-positive donor",
        "Median baseline HCV RNA level",
        "Time from transplant"
      ],
      "remaining_candidate_features": [
        "body mass index (BMI)",
        "chronic kidney disease (CKD) stage",
        "HCV viremia",
        "HCV antibody positivity",
        "creatinine level",
        "glomerular filtration rate (GFR)",
        "albumin level",
        "platelet count",
        "aspartate aminotransferase (AST) level",
        "alanine aminotransferase (ALT) level",
        "Child-Pugh class",
        "history of clinically significant allergy or adverse event with protease inhibitors",
        "history of liver disease caused by an etiology other than HCV",
        "history of hepatocellular carcinoma",
        "history of HIV co-infection",
        "history of prior exposure to HCV protease inhibitor therapy"
      ]
    },
    "processed-gen-response": "Age, sex, race, ethnicity, body mass index (BMI), chronic kidney disease (CKD) stage, genotype 1 HCV infection, HCV viremia, HCV antibody positivity, liver disease staging, creatinine level, glomerular filtration rate (GFR), albumin level, platelet count, aspartate aminotransferase (AST) level, alanine aminotransferase (ALT) level, Child-Pugh class, history of clinically significant allergy or adverse event with protease inhibitors, history of liver disease caused by an etiology other than HCV, history of hepatocellular carcinoma, history of HIV co-infection, history of prior exposure to HCV protease inhibitor therapy."
  }
}